Fox Run Management, L.L.C. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$83.14 - $145.99 $222,565 - $390,815	-2,677 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$110.08 - $142.92 $294,684 - $382,596	2,677 New	2,677 $317,000
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $475,567 - $668,296	-4,811 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$65.78 - $105.02 $316,467 - $505,251	4,811 New	4,811 $467,000
Q1 2020 May 08, 2020	SELL	$27.51 - $57.29 $166,958 - $347,693	-6,069 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$40.86 - $57.65 $157,270 - $221,894	-3,849 Reduced 38.81%	6,069 $330,000
Q2 2019 Jul 17, 2019	BUY	$39.79 - $67.01 $394,637 - $664,605	9,918 New	9,918 $434,000

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $2.8B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.